Surfactant Administration via Thin Catheter
Peter A. Dargaville
Harley Mason
A. Definitions
Respiratory distress syndrome (RDS): The clinical manifestation of surfactant deficiency in the preterm lung, cardinal features being tachypnea, retractions, grunting, and need for oxygen.
Thin catheter: A catheter of external diameter ˜1.3 to 1.7 mm (4 to 5 FG) used for the purpose of surfactant instillation.
B. Purpose
To administer exogenous surfactant by thin catheter to a preterm infant with RDS receiving noninvasive respiratory support, most usually nasal continuous positive airway pressure (CPAP).
C. Background
Exogenous surfactant has been a mainstay of therapy for the preterm infant with RDS for over 30 years, delivered via an endotracheal tube with dose repetition as necessary. Nowadays, however, many preterm infants are managed from the outset on noninvasive respiratory support, in particular nasal CPAP, and thus lack the usual conduit by which surfactant is administered. Amongst infants on CPAP, many of those with RDS are adequately supported with CPAP alone, with gradual improvement in surfactant status and thus lung function. Some infants continue to exhibit features of RDS, including significant oxygen requirements, raising the dilemma of whether to continue with CPAP or to intubate for the purpose of giving surfactant.
Whilst the obvious resolution of the CPAP-surfactant dilemma is to briefly intubate for surfactant delivery, several recent randomized controlled trials have not shown a major benefit of this approach, mostly related to difficulty with extubation (1, 2). For this reason, a number of different techniques of delivering surfactant in a nonintubated spontaneously breathing infant have been pursued (3, 4). There is now wide experience of surfactant administration via a thin catheter briefly placed in the trachea (5, 6, 7), and enthusiasm for this method is burgeoning. A number of randomized controlled trials have suggested that this approach is a more effective means of delivering surfactant than standard intubation (8, 9), most likely related to a positive effect of spontaneous breathing on surfactant distribution.
Two main methods of thin catheter placement for surfactant delivery have emerged, both of which are performed with the aid of direct laryngoscopy.
1. The Cologne method, in which the tip of a flexible feeding tube is directed through the vocal cords with Magill forceps (10)
2. The Hobart method, where the tip of a semirigid catheter (e.g., a vascular catheter) is guided into the trachea without Magill forceps (11)
Numerous variations on these methods now exist.
D. Indications
The indications for surfactant therapy via thin catheter are yet to be fully resolved. Nevertheless, based on the results of nonrandomized studies and clinical trials (12), the following gestation-specific thresholds for therapy can be provided.
1. All gestations:
Respiratory insufficiency thought to be related to RDS and managed with noninvasive respiratory support, most usually CPAP or a form of noninvasive positive pressure ventilation.
2. 23 to 25 weeks’ gestation
a. CPAP level ≥6 cm H2O.
b. Any requirement for oxygen to maintain SpO2 in the local target range.
c. Age <6 hours, and preferably <2 hours.
3. 26 to 28 weeks’ gestation
a. CPAP level ≥6 cm H2O.
b. FiO2 ≥0.30 to maintain SpO2 in the local target range.
c. Age <24 hours, with an emphasis on early recognition and treatment at an age <6 to 12 hours.
4. Beyond 28 weeks’ gestation
a. CPAP level ≥6 cm H2O, or nasal high flow ≥7 L/min.
b. FiO2 ≥0.30 to 0.35 to maintain SpO2 in the local target range.
c. Age <24 hours.
E. Contraindications
1. Absolute contraindications
a. Severe RDS with high oxygen requirements and/or severe respiratory acidosis, along with prominent atelectasis radiographically, such that ongoing ventilatory support will be necessary after surfactant therapy. The suggested FiO2 thresholds above which intubation for surfactant should be considered for surfactant delivery are >0.40 to 0.50 at gestations <30 weeks, and FiO2 >0.60 for more mature infants.
b. An alternative cause for respiratory distress (e.g., congenital pneumonia or pulmonary hypoplasia).
c. Maxillofacial, tracheal, or known pulmonary malformations.
d. No experienced personnel available to perform the tracheal catheterization.
FIGURE 39.1 Equipment. A: Equipment for Cologne method. B: Equipment for Hobart method. The catheter depicted is the LISAcath; if not available a 16G vascular catheter (Angiocath) is a satisfactory alternative.
Stay updated, free articles. Join our Telegram channelFull access? Get Clinical TreeGet Clinical Tree app for offline access |